Results 121 to 130 of about 2,831 (235)

Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno‐associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation

Journal of Ophthalmology, Volume 2024, Issue 1, 2024.
Corneal diseases represent 5.1% of all eye defects and are the fourth leading cause of blindness globally. Corneal neovascularization can arise from all conditions of chronic irritation or hypoxia, which disrupts the immune‐privileged state of the healthy cornea, increases the risk of rejection after keratoplasty, and leads to opacity.
Mengzhen Xie, Lixiang Wang, Yingping Deng, Ke Ma, Hongbo Yin, Xiaolan Zhang, Xingye Xiang, Jing Tang, Yedi Zhou   +8 more
wiley   +1 more source

Effect of Conbercept Treatment on Macular Edema and Microvascular Structure in Eyes with Retinal Vein Occlusions

International Journal of General Medicine, 2022
Xiaoxia Ding, Yu Wang, Bo Zou, Dongxiao Zang, Yi Hao Department of Ophthalmology, Fushun Eye Hospital, Fushun, Liaoning, People’s Republic of ChinaCorrespondence: Xiaoxia Ding, Fushun Eye Hospital, No.
Ding X, Wang Y, Zou B, Zang D, Hao Y
doaj  

Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis [PDF]

Background: Proliferative diabetic retinopathy is a major cause of sight loss in people with diabetes, with a high risk of vitreous haemorrhage, tractional retinal detachment and other complications. Panretinal photocoagulation is the primary established
Bojke L, Dias S, Figueira JP, Fulbright H, Hodgson R, Lawrenson JG, Llewellyn A, Peto T, Rush T, Simmonds M, Sivaprasad S, Steel D, Stewart L, Walker R, Walton M   +14 more
core   +1 more source

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION [PDF]

, 2017
Purpose: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration.
de Andrade, Gabriel Costa, de Oliveira Dias, Joao Rafael, Farah, Michel Eid, Kniggendorf, Vinicius Ferreira, Maia, Andre, Meyer, Carsten, Novais, Eduardo Amorim, Rodrigues, Eduardo Buschele, Watanabe, Sung Eun Song   +8 more
core   +1 more source

Intravitreal Conbercept or Ranibizumab for myopic choroidal neovascularization

, 2022
Caiyun Zhang, Chu-Lan Li, Jianbo Mao, Li-Jun Shen   +3 more
openalex   +2 more sources

Efficacy of conbercept combined with panretinal photocoagulation in the treatment of proliferative diabetic retinopathy [PDF]

, 2020
He F, Jingyun Yang, Xiao Zhang, Weihong Yu   +3 more
openalex   +1 more source

Retraction: Clinical Efficacy Analysis of Conbercept Intravitreal Injection for Fundus Diseases Based on Computer Simulation (J. Phys.: Conf. Ser. 1744 032041)

, 2021

openalex   +1 more source

Corrigendum: Efficacy of Initial vs. Delayed Photodynamic Therapy in Combination With Conbercept for Polypoidal Choroidal Vasculopathy [PDF]

, 2022
Zuhua Sun, Yuanyuan Gong, Yating Yang, Ying Huang, Suqin Yu, Junqing Pei, Bing Lin, Rong Zhou, Yingzi Li, Yumin Li, Junyan Zhang, Xiaoling Liu   +11 more
openalex   +1 more source

Intravitreal bevacizumab for the treatment of choroidal haemangiomas [PDF]

Purpose: To investigate the use of intravitreal bevacizumab for the treatment of subretinal (SRF) and intraretinal fluid associated with circumscribed choroidal haemangiomas (CCH). // Methods: This was a retrospective review of all patients treated
Elkayal, Hassan E, Negretti, Guy S, Sagoo, Mandeep S   +2 more
core  

Actualizació en el maneig de la degeneració macular associada a l'edat [PDF]

, 2021
La DMAE és considera la principal causa de ceguera en el món occidental i en el món s’estima que hi ha entre 30 i 50 milions de persones que la pateixen i s'espera un augment d’aquesta xifra a causa de l'envelliment de la població.
Ferreres Palatsí, Maria
core